Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mineralys Therapeutics, Inc. (MLYS)
USD26.98
-0.30 (-1.11%)
US NASDAQ Healthcare Biotechnology
Address
150 N. Radnor Chester Rd. 19087
Radnor, PA, US
Radnor, PA, US
CEO
Jon Congleton
Website
mineralystx.com
IPO
2023-02-10
CIK 1933414 ISIN US6031701013
Description
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD26.98
-0.30 (-1.11%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.57
Float Shares
46.17M
Free Float %
69.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.64% | +1.88% | +11.68% | +6.71% | -37.19% | -18.08% | +98.07% | +84.09% | +61.23% | +61.23% | +61.23% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
26.98
Low
30.00
+11.2%
Consensus
46.00
+70.5%
Median
52.00
+92.8%
High
56.00
+107.6%
DCF (Unlevered)
2.53
-90.6%
DCF (Levered)
2.56
-90.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
90% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 9 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
43.00
+59.4%
|
| Last Year | 5 |
47.60
+76.4%
|
| All Time | 7 |
44.29
+64.2%
|
Quality scores
Altman Z-Score
79.10
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+37.4% ★ Q1'26: +40.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +2,291.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+39.4% Q1'26: +55.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 6 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 7 Rev. Ana. 5 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 6 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
557.1K
342.3K – 1.19M
|
121.38M
110.26M – 132.50M
+21,686.9% YoY
|
254.69M
254.69M – 254.69M
+109.8% YoY
|
681.99M
419.00M – 1.46B
+167.8% YoY
|
1.13B
693.88M – 2.42B
+65.6% YoY
|
| EBITDA |
-192.36M
|
-170.55M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-192.40M
|
-170.60M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-177.81M
est: -190.77M (+6.8%)
|
-154.65M
est: -151.78M (-1.9%)
|
-156.87M
-173.31M – -140.43M
-3.4% YoY
|
-183.58M
-259.36M – 92.24M
-17.0% YoY
|
-95.02M
-118.50M – -24.95M
+48.2% YoY
|
121.10M
60.39M – 300.85M
+227.4% YoY
|
284.29M
141.77M – 706.23M
+134.7% YoY
|
| SGA |
23.82M
|
38.60M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.66
est: -3.71 (+1.4%)
|
-2.29
est: -2.39 (+4.0%)
|
-2.32
-2.56 – -2.08
+2.8% YoY
|
-2.08
-3.83 – 1.36
+10.3% YoY
|
-1.18
-1.75 – -0.37
+43.2% YoY
|
1.79
0.89 – 4.45
+251.7% YoY
|
4.20
2.10 – 10.44
+134.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
27
Total invested
44.99M
Insider transactions (90d)
1
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Brian Taylor Slingsby | 9.21M | 22.40% | — | 9.21M | — | — | IN | — | 2024-02-13 | ↗ |
| 2 | Catalys Pacific Fund GP, LP | 9.21M | 22.40% | — | 9.21M | — | — | PN | Cayman Islands | 2024-02-13 | ↗ |
| 3 | Catalys Pacific Fund, LP | 9.21M | 22.40% | — | 9.21M | — | — | PN | — | 2024-02-13 | ↗ |
| 4 | Catalys Pacific, LLC | 9.21M | 22.40% | — | 9.21M | — | — | OO | — | 2024-02-13 | ↗ |
| 5 | Srinivas Akkaraju | 4.52M | 11.10% | 2.4K | 4.52M | 2.4K | 11.00 | IN | — | 2023-02-24 | ↗ |
| 6 | Samsara BioCapital GP, LLC | 4.52M | 11.10% | — | 4.52M | — | 11.00 | OO | — | 2023-02-24 | ↗ |
| 7 | Samsara BioCapital, L.P. | 4.52M | 11.10% | — | 4.52M | — | 10.00 | PN | Delaware | 2023-02-24 | ↗ |
| 8 | Chen Yu | 3.19M | 6.40% | — | 3.19M | — | 3.19M | IN | Delaware | 2024-02-15 | ↗ |
| 9 | TCG Crossover Fund II, L.P. | 3.19M | 6.40% | — | 3.19M | — | 3.19M | PN | Delaware | 2024-02-15 | ↗ |
| 10 | TCG Crossover GP II, LLC | 3.19M | 6.40% | — | 3.19M | — | 3.19M | OO | Delaware | 2024-02-15 | ↗ |
| 11 | Peter Kolchinsky | 3.18M | 7.80% | — | 3.18M | — | 11.00 | HC, IN | — | 2023-02-24 | ↗ |
| 12 | RA Capital Management, L.P. | 3.18M | 7.80% | — | 3.18M | — | 11.00 | IA, PN | — | 2023-02-24 | ↗ |
| 13 | Rajeev Shah | 3.18M | 7.80% | — | 3.18M | — | 11.00 | HC, IN | — | 2023-02-24 | ↗ |
| 14 | Andera Partners | 2.87M | 7.00% | — | 2.87M | — | — | OO | — | 2023-02-24 | ↗ |
| 15 | BioDiscovery 6 FPCI | 2.87M | 7.00% | — | 2.87M | — | — | OO | — | 2023-02-24 | ↗ |
| 16 | Laurent Tourtois | 2.87M | 7.00% | — | 2.87M | — | — | IN | — | 2023-02-24 | ↗ |
| 17 | Raphaël Wisniewski | 2.87M | 7.00% | — | 2.87M | — | — | IN | France | 2023-02-24 | ↗ |
| 18 | Adams Street Partners, LLC | 2.30M | 5.60% | 2.30M | — | 2.30M | — | IA | Delaware | 2024-02-14 | ↗ |
| 19 | HBM Healthcare Investments (Cayman) Ltd. | 2.25M | 5.50% | 2.25M | — | 2.25M | — | CO | Cayman Islands, British West Indies | 2024-02-13 | ↗ |
| 20 | Adams Street Growth Equity Fund VII LP | 892.8K | 2.17% | 892.8K | — | 892.8K | — | PN | Delaware | 2024-02-14 | ↗ |
| 21 | Adams Street 2018 Direct Venture/Growth Fund LP | 358.7K | 0.87% | 358.7K | — | 358.7K | — | PN | Delaware | 2024-02-14 | ↗ |
| 22 | Adams Street 2017 Direct Venture/Growth Fund LP | 240.2K | 0.58% | 240.2K | — | 240.2K | — | PN | Delaware | 2024-02-14 | ↗ |
| 23 | Adams Street 2020 Direct Growth Equity Fund LP | 214.9K | 0.52% | 214.9K | — | 214.9K | — | PN | Delaware | 2024-02-14 | ↗ |
| 24 | Adams Street 2021 Direct Growth Equity Fund LP | 208.5K | 0.51% | 208.5K | — | 208.5K | — | PN | Delaware | 2024-02-14 | ↗ |
| 25 | Adams Street 2019 Direct Growth Equity Fund LP | 201.5K | 0.49% | 201.5K | — | 201.5K | — | PN | Delaware | 2024-02-14 | ↗ |
| 26 | Adams Street 2016 Direct Venture/Growth Fund LP | 185.7K | 0.45% | 185.7K | — | 185.7K | — | PN | Delaware | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
27
-211 vs prev Q
New positions
6
Closed positions
203
Increased
15
Reduced
5
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ANDERA PARTNERS | 1.59M +1.6M (+100.0%) | 57.77B +57.8B (+100.0%) | 2.26% +2.255 pp | 32.71% +32.711 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 2 | — | 174.3K +174.3K (+100.0%) | 6.33B +6.3B (+100.0%) | 0.25% +0.247 pp | 4.45% +4.452 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 3 | CATALYS PACIFIC, LLC | 7.90M -1.0M (-11.2%) | 286.83M -50.8M (-15.0%) | 11.20% -2.408 pp | 92.37% -3.725 pp | USD8.81 +311.9% | 9 qtrs — |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 7.32M +— (+0.0%) | 265.78M -11.9M (-4.3%) | 10.37% -0.815 pp | 2.72% -0.699 pp | USD18.67 +94.4% | 12 qtrs — |
| 5 | SAMSARA BIOCAPITAL, LLC | 5.87M -392.1K (-6.3%) | 213.06M -24.4M (-10.3%) | 8.32% -1.253 pp | 21.98% -9.026 pp | USD17.54 +106.9% | 12 qtrs — |
| 6 | FMR LLC | 5.06M +3.0M (+144.2%) | 183.54M +105.0M (+133.7%) | 7.16% +4.000 pp | 0.01% +0.005 pp | USD35.41 +2.5% | 12 qtrs — |
| 7 | BLACKROCK, INC. | 4.33M +656.1K (+17.9%) | 157.05M +17.8M (+12.8%) | 6.13% +0.521 pp | 0.00% +0.000 pp | USD19.68 +84.4% | 6 qtrs — |
| 8 | VANGUARD GROUP INC | 3.35M +333.9K (+11.1%) | 121.68M +7.2M (+6.3%) | 4.75% +0.137 pp | 0.00% +0.000 pp | USD21.46 +69.1% | 12 qtrs — |
| 9 | STATE STREET CORP | 3.18M +1.9M (+144.4%) | 115.58M +66.2M (+133.9%) | 4.51% +2.521 pp | 0.00% +0.002 pp | USD26.93 +34.8% | 12 qtrs — |
| 10 | CALIGAN PARTNERS LP | 2.77M +— (+0.0%) | 100.62M -4.5M (-4.3%) | 3.93% -0.309 pp | 8.28% -5.488 pp | USD20.61 +76.1% | 7 qtrs — |
| 11 | FRANKLIN RESOURCES INC | 1.79M -21.0K (-1.2%) | 64.91M -3.7M (-5.4%) | 2.53% -0.231 pp | 0.02% -0.001 pp | USD12.81 +183.3% | 12 qtrs — |
| 12 | LAURION CAPITAL MANAGEMENT LP | 1.71M -7.0K (-0.4%) | 62.18M -3.1M (-4.7%) | 2.43% -0.201 pp | 2.32% +1.194 pp | USD13.66 +165.7% | 12 qtrs — |
| 13 | HOLOCENE ADVISORS, LP | 1.60M +396.7K (+32.9%) | 58.14M +12.4M (+27.2%) | 2.27% +0.428 pp | 0.12% +0.018 pp | USD37.52 -3.3% | 2 qtrs — |
| 14 | SR ONE CAPITAL MANAGEMENT, LP | 1.56M -550.0K (-26.0%) | 56.76M -23.4M (-29.2%) | 2.22% -1.014 pp | 8.03% -3.559 pp | USD15.55 +133.4% | 12 qtrs — |
| 15 | SUVRETTA CAPITAL MANAGEMENT, LLC | 1.54M -593.5K (-27.8%) | 55.84M -25.0M (-30.9%) | 2.18% -1.078 pp | 1.14% -0.926 pp | USD19.80 +83.3% | 4 qtrs — |
| 16 | GOLDMAN SACHS GROUP INC | 1.45M +739.3K (+103.9%) | 52.65M +25.7M (+95.1%) | 2.06% +0.968 pp | 0.01% +0.003 pp | USD26.64 +36.2% | 12 qtrs — |
| 17 | POLAR CAPITAL HOLDINGS PLC | 1.40M +342.4K (+32.3%) | 50.85M +10.7M (+26.6%) | 1.98% +0.367 pp | 0.20% +0.003 pp | USD37.52 -3.3% | 2 qtrs — |
| 18 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.33M +1.3M (+6,097.1%) | 48.09M +47.3M (+5,829.6%) | 1.88% +1.844 pp | 0.01% +0.005 pp | USD35.95 +0.9% | 5 qtrs — |
| 19 | SAMLYN CAPITAL, LLC | 1.30M +1.3M (+100.0%) | 47.36M +47.4M (+100.0%) | 1.85% +1.849 pp | 0.75% +0.754 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 20 | JENNISON ASSOCIATES LLC | 1.26M +882.3K (+234.4%) | 45.68M +31.4M (+220.1%) | 1.78% +1.208 pp | 0.03% +0.019 pp | USD29.59 +22.6% | 7 qtrs — |
| 21 | GEODE CAPITAL MANAGEMENT, LLC | 1.26M +134.2K (+11.9%) | 45.64M +3.0M (+7.1%) | 1.78% +0.065 pp | 0.00% +0.000 pp | USD19.45 +86.6% | 12 qtrs — |
| 22 | CAPTION MANAGEMENT, LLC | 1.22M +901.8K (+281.8%) | 44.34M +32.2M (+265.4%) | 1.73% +1.242 pp | 0.30% +0.209 pp | USD35.72 +1.6% | 3 qtrs — |
| 23 | JANUS HENDERSON GROUP PLC | 1.21M +1.2M (+6,012.8%) | 44.01M +43.3M (+5,747.6%) | 1.72% +1.688 pp | 0.02% +0.019 pp | USD36.08 +0.6% | 3 qtrs — |
| 24 | POINT72 ASSET MANAGEMENT, L.P. | 1.21M -592.4K (-32.9%) | 43.81M -24.4M (-35.8%) | 1.71% -1.040 pp | 0.05% -0.065 pp | USD37.92 -4.3% | 2 qtrs — |
| 25 | CAPITAL INTERNATIONAL INVESTORS | 1.16M -1.2M (-51.4%) | 42.22M -48.5M (-53.5%) | 1.65% -2.009 pp | 0.01% -0.008 pp | USD13.53 +168.2% | 3 qtrs — |
| 26 | D. E. SHAW & CO., INC. | 1.15M +539.7K (+88.3%) | 41.76M +18.6M (+80.3%) | 1.63% +0.697 pp | 0.02% +0.010 pp | USD25.96 +39.8% | 4 qtrs — |
| 27 | BOOTHBAY FUND MANAGEMENT, LLC | 992.1K +49.5K (+5.2%) | 36.00M +258.3K (+0.7%) | 1.41% -0.035 pp | 0.54% +0.017 pp | USD17.54 +106.9% | 7 qtrs — |
| 28 | BANK OF AMERICA CORP /DE/ | 987.3K +219.0K (+28.5%) | 35.83M +6.7M (+23.0%) | 1.40% +0.225 pp | 0.00% +0.001 pp | USD30.95 +17.3% | 12 qtrs — |
| 29 | ORBIMED ADVISORS LLC | 980.4K -489.1K (-33.3%) | 35.58M -20.1M (-36.2%) | 1.39% -0.856 pp | 0.73% -0.584 pp | USD25.30 +43.4% | 8 qtrs — |
| 30 | ALLIANCEBERNSTEIN L.P. | 922.5K +40.1K (+4.5%) | 33.48M +16.9K (+0.1%) | 1.31% -0.041 pp | 0.01% +0.000 pp | USD37.12 -2.2% | 11 qtrs — |
| 31 | AMERICAN CENTURY COMPANIES INC | 908.1K +28.4K (+3.2%) | 32.95M -402.9K (-1.2%) | 1.29% -0.058 pp | 0.02% 0.000 pp | USD14.76 +145.9% | 12 qtrs — |
| 32 | PICTET ASSET MANAGEMENT HOLDING SA | 852.9K -76.3K (-8.2%) | 30.95M -4.3M (-12.2%) | 1.21% -0.212 pp | 0.03% -0.004 pp | USD15.78 +130.0% | 4 qtrs — |
| 33 | FARALLON CAPITAL MANAGEMENT LLC | 823.3K -849.8K (-50.8%) | 29.88M -33.6M (-52.9%) | 1.17% -1.390 pp | 0.14% -0.119 pp | USD37.92 -4.3% | 2 qtrs — |
| 34 | WELLINGTON MANAGEMENT GROUP LLP | 784.3K +822.0 (+0.1%) | 28.46M -1.2M (-4.2%) | 1.11% -0.086 pp | 0.01% 0.000 pp | USD34.26 +5.9% | 6 qtrs — |
| 35 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 750.0K -750.0K (-50.0%) | 27.22M -29.7M (-52.1%) | 1.06% -1.229 pp | 1.35% -2.497 pp | USD14.35 +152.9% | 6 qtrs — |
| 36 | AFFINITY ASSET ADVISORS, LLC | 730.0K -20.0K (-2.7%) | 26.49M -1.9M (-6.9%) | 1.03% -0.112 pp | 1.51% -0.968 pp | USD14.95 +142.7% | 8 qtrs — |
| 37 | SIREN, L.L.C. | 700.0K +700.0K (+100.0%) | 25.40M +25.4M (+100.0%) | 0.99% +0.992 pp | 0.76% +0.758 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 38 | CANDRIAM S.C.A. | 678.4K +110.6K (+19.5%) | 24.62M +3.1M (+14.3%) | 0.96% +0.094 pp | 0.12% +0.010 pp | USD18.17 +99.7% | 5 qtrs — |
| 39 | ARMISTICE CAPITAL, LLC | 676.0K +168.4K (+33.2%) | 24.53M +5.3M (+27.4%) | 0.96% +0.182 pp | 0.29% +0.006 pp | USD31.09 +16.7% | 3 qtrs — |
| 40 | NATIONALE-NEDERLANDEN POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. | 659.1K +659.1K (+100.0%) | 23.92M +23.9M (+100.0%) | 0.93% +0.934 pp | 2.12% +2.123 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 41 | MORGAN STANLEY | 639.5K -737.5K (-53.6%) | 23.21M -29.0M (-55.6%) | 0.91% -1.198 pp | 0.00% -0.002 pp | USD26.10 +39.0% | 12 qtrs — |
| 42 | TWO SIGMA INVESTMENTS, LP | 610.4K +610.4K (+100.0%) | 22.15M +22.2M (+100.0%) | 0.86% +0.865 pp | 0.03% +0.031 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 43 | TUDOR INVESTMENT CORP ET AL | 586.1K +586.1K (+100.0%) | 21.27M +21.3M (+100.0%) | 0.83% +0.830 pp | 0.04% +0.039 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 44 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 570.8K +533.8K (+1,442.7%) | 20.71M +19.3M (+1,376.4%) | 0.81% +0.752 pp | 0.00% +0.002 pp | USD35.40 +2.5% | 4 qtrs — |
| 45 | QUBE RESEARCH & TECHNOLOGIES LTD | 496.5K +316.1K (+175.2%) | 18.02M +11.2M (+163.4%) | 0.70% +0.428 pp | 0.02% +0.011 pp | USD28.02 +29.5% | 3 qtrs — |
| 46 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 461.3K +52.1K (+12.7%) | 16.74M +1.2M (+7.9%) | 0.65% +0.028 pp | 0.00% +0.000 pp | USD20.78 +74.6% | 12 qtrs — |
| 47 | SPHERA FUNDS MANAGEMENT LTD. | 449.0K +229.1K (+104.2%) | 16.29M +8.0M (+95.4%) | 0.64% +0.300 pp | 3.15% +1.391 pp | USD25.59 +41.8% | 12 qtrs — |
| 48 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 427.6K +19.3K (+4.7%) | 15.52M +34.2K (+0.2%) | 0.61% -0.018 pp | 0.80% -0.109 pp | USD21.10 +72.0% | 4 qtrs — |
| 49 | PARKMAN HEALTHCARE PARTNERS LLC | 410.2K -45.3K (-9.9%) | 14.89M -2.4M (-13.8%) | 0.58% -0.115 pp | 1.42% -0.385 pp | USD15.02 +141.6% | 4 qtrs — |
| 50 | CITADEL ADVISORS LLC | 399.9K -1.7M (-80.7%) | 14.51M -63.9M (-81.5%) | 0.57% -2.592 pp | 0.00% -0.010 pp | USD37.77 -3.9% | 12 qtrs — |
| 51 | TIMESSQUARE CAPITAL MANAGEMENT, LLC | 380.1K +380.1K (+100.0%) | 13.79M +13.8M (+100.0%) | 0.54% +0.538 pp | 0.21% +0.208 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 52 | 22NW, LP | 358.3K +— (+0.0%) | 13.00M -584.1K (-4.3%) | 0.51% -0.040 pp | 5.47% -0.928 pp | USD15.47 +134.6% | 4 qtrs — |
| 53 | TWO SIGMA ADVISERS, LP | 353.7K +353.7K (+100.0%) | 12.84M +12.8M (+100.0%) | 0.50% +0.501 pp | 0.03% +0.025 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 54 | CATALIO CAPITAL MANAGEMENT, LP | 331.8K +331.8K (+100.0%) | 12.04M +12.0M (+100.0%) | 0.47% +0.470 pp | 2.13% +2.129 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 55 | RENAISSANCE TECHNOLOGIES LLC | 322.1K +274.7K (+579.5%) | 11.69M +9.9M (+550.3%) | 0.46% +0.384 pp | 0.02% +0.016 pp | USD32.87 +10.4% | 10 qtrs — |
| 56 | LORD, ABBETT & CO. LLC | 312.4K +312.4K (+100.0%) | 11.34M +11.3M (+100.0%) | 0.44% +0.443 pp | 0.03% +0.035 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 57 | NORTHERN TRUST CORP | 299.9K -90.9K (-23.3%) | 10.88M -3.9M (-26.6%) | 0.42% -0.172 pp | 0.00% -0.001 pp | USD16.63 +118.2% | 12 qtrs — |
| 58 | STEMPOINT CAPITAL LP | 290.0K +131.9K (+83.4%) | 10.53M +4.5M (+75.6%) | 0.41% +0.169 pp | 1.80% +0.604 pp | USD23.88 +52.0% | 5 qtrs — |
| 59 | IRON TRIANGLE PARTNERS LP | 257.1K +257.1K (+100.0%) | 9.33M +9.3M (+100.0%) | 0.36% +0.364 pp | 1.07% +1.067 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 60 | MARSHALL WACE, LLP | 249.1K +249.1K (+100.0%) | 9.04M +9.0M (+100.0%) | 0.35% +0.353 pp | 0.01% +0.008 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 61 | SQUAREPOINT OPS LLC | 246.8K +203.8K (+473.8%) | 8.96M +7.3M (+449.1%) | 0.35% +0.284 pp | 0.01% +0.008 pp | USD35.44 +2.4% | 3 qtrs — |
| 62 | SG AMERICAS SECURITIES, LLC | 230.8K +130.8K (+130.7%) | 8.38M +4.6M (+120.8%) | 0.33% +0.174 pp | 0.01% -0.002 pp | USD26.38 +37.6% | 6 qtrs — |
| 63 | MILLENNIUM MANAGEMENT LLC | 225.0K +225.0K (+100.0%) | 8.17M +8.2M (+100.0%) | 0.32% +0.319 pp | 0.00% +0.003 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 64 | BARCLAYS PLC | 223.3K +185.1K (+484.2%) | 8.10M +7.6M (+1,650.8%) | 0.32% +0.258 pp | 0.00% +0.002 pp | USD32.32 +12.3% | 12 qtrs — |
| 65 | SWEDBANK AB | 221.4K -77.9K (-26.0%) | 8.03M -3.3M (-29.2%) | 0.31% -0.144 pp | 0.01% -0.004 pp | USD15.54 +133.5% | 4 qtrs — |
| 66 | UBS GROUP AG | 201.3K +111.8K (+124.9%) | 7.30M +3.9M (+115.2%) | 0.29% +0.148 pp | 0.00% +0.001 pp | USD25.94 +39.9% | 11 qtrs — |
| 67 | IKARIAN CAPITAL, LLC | 200.0K +200.0K (+100.0%) | 7.26M +7.3M (+100.0%) | 0.28% +0.283 pp | 0.57% +0.567 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 68 | RUSSELL INVESTMENTS GROUP, LTD. | 175.4K +172.1K (+5,272.6%) | 6.36M +6.2M (+5,041.7%) | 0.25% +0.243 pp | 0.01% +0.007 pp | USD36.32 -0.1% | 3 qtrs — |
| 69 | BNP PARIBAS ARBITRAGE, SNC | 172.9K -453.2K (-72.4%) | 6.28M -17.5M (-73.6%) | 0.25% -0.712 pp | 0.00% -0.010 pp | USD37.77 -3.9% | 5 qtrs — |
| 70 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 151.0K -24.6K (-14.0%) | 5.48M -1.2M (-17.7%) | 0.21% -0.054 pp | 3.18% -3.076 pp | USD15.68 +131.4% | 4 qtrs — |
| 71 | BURKEHILL GLOBAL MANAGEMENT, LP | 150.0K +— (+0.0%) | 5.44M -244.5K (-4.3%) | 0.21% -0.017 pp | 0.36% +0.035 pp | USD37.92 -4.3% | 2 qtrs — |
| 72 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 142.6K -22.4K (-13.6%) | 5.17M -1.1M (-17.3%) | 0.20% -0.050 pp | 0.48% -0.209 pp | USD37.92 -4.3% | 2 qtrs — |
| 73 | ARTIA GLOBAL PARTNERS LP | 137.8K +81.2K (+143.5%) | 5.00M +2.9M (+133.0%) | 0.20% +0.109 pp | 0.80% +0.458 pp | USD29.68 +22.3% | 3 qtrs — |
| 74 | DIMENSIONAL FUND ADVISORS LP | 137.6K -9.1K (-6.2%) | 4.99M -575.1K (-10.3%) | 0.20% -0.029 pp | 0.00% 0.000 pp | USD14.23 +155.0% | 5 qtrs — |
| 75 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 139.3K +139.3K (+100.0%) | 4.98M +5.0M (+100.0%) | 0.20% +0.197 pp | 0.05% +0.054 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 76 | ADAR1 CAPITAL MANAGEMENT, LLC | 136.2K +58.0K (+74.1%) | 4.94M +2.0M (+66.6%) | 0.19% +0.073 pp | 0.36% +0.084 pp | USD22.53 +61.1% | 8 qtrs — |
| 77 | BANK OF NEW YORK MELLON CORP | 131.8K +18.0K (+15.9%) | 4.78M +469.3K (+10.9%) | 0.19% +0.013 pp | 0.00% +0.000 pp | USD19.88 +82.5% | 12 qtrs — |
| 78 | RAFFERTY ASSET MANAGEMENT, LLC | 127.9K +96.2K (+303.7%) | 4.64M +3.4M (+286.4%) | 0.18% +0.133 pp | 0.02% +0.012 pp | USD30.65 +18.4% | 3 qtrs — |
| 79 | SCHRODER INVESTMENT MANAGEMENT GROUP | 130.6K +130.6K (+100.0%) | 4.64M +4.6M (+100.0%) | 0.19% +0.185 pp | 0.00% +0.004 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 80 | HIGHVISTA STRATEGIES LLC | 124.5K -85.3K (-40.6%) | 4.52M -3.4M (-43.2%) | 0.18% -0.144 pp | 1.16% -0.786 pp | USD20.47 +77.3% | 3 qtrs — |
| 81 | NUVEEN, LLC | 122.9K +36.0K (+41.5%) | 4.46M +1.2M (+35.4%) | 0.17% +0.041 pp | 0.00% +0.000 pp | USD23.34 +55.5% | 4 qtrs — |
| 82 | JANE STREET GROUP, LLC | 117.4K +117.4K (+100.0%) | 4.26M +4.3M (+100.0%) | 0.17% +0.166 pp | 0.00% +0.001 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 83 | SIMPLIFY ASSET MANAGEMENT INC. | 114.2K -104.5K (-47.8%) | 4.14M -4.2M (-50.0%) | 0.16% -0.172 pp | 0.07% -0.085 pp | USD37.92 -4.3% | 2 qtrs — |
| 84 | NANTAHALA CAPITAL MANAGEMENT, LLC | 113.3K -45.4K (-28.6%) | 4.11M -1.9M (-31.7%) | 0.16% -0.082 pp | 0.14% -0.073 pp | USD13.26 +173.7% | 8 qtrs — |
| 85 | TREXQUANT INVESTMENT LP | 112.8K +68.8K (+156.5%) | 4.09M +2.4M (+145.5%) | 0.16% +0.093 pp | 0.04% +0.019 pp | USD28.05 +29.4% | 4 qtrs — |
| 86 | VOYA INVESTMENT MANAGEMENT LLC | 112.7K -25.9K (-18.7%) | 4.09M -1.2M (-22.2%) | 0.16% -0.052 pp | 0.00% -0.001 pp | USD29.31 +23.8% | 4 qtrs — |
| 87 | ENSIGN PEAK ADVISORS, INC | 112.2K +4.6K (+4.2%) | 4.07M -10.3K (-0.3%) | 0.16% -0.006 pp | 0.01% +0.001 pp | USD15.24 +138.1% | 12 qtrs — |
| 88 | DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN | 111.8K +111.8K (+100.0%) | 4.06M +4.1M (+100.0%) | 0.16% +0.158 pp | 0.00% +0.004 pp | USD36.29 +0.0% | 1 qtrs NEW |
| 89 | EAM INVESTORS, LLC | 96.1K -31.4K (-24.6%) | 3.49M -1.3M (-26.7%) | 0.14% -0.059 pp | 0.39% -0.157 pp | USD37.92 -4.3% | 4 qtrs — |
| 90 | SILVERARC CAPITAL MANAGEMENT, LLC | 95.0K +15.0K (+18.7%) | 3.45M +413.3K (+13.6%) | 0.13% +0.012 pp | 0.48% +0.070 pp | USD19.10 +90.0% | 4 qtrs — |
| 91 | SWISS NATIONAL BANK | 90.1K +1.6K (+1.8%) | 3.27M -86.2K (-2.6%) | 0.13% -0.008 pp | 0.00% +0.000 pp | USD21.13 +71.7% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 101 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 1.28% | 2.72M | 0.50% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 0.74% | 266.5K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 0.74% | 80.27M | 0.35% |
| 4 | Virtus Biotech Clinical Trials ETF BBC | 0.74% | 425.7K | 0.65% |
| 5 | American Century Small Cap Growth Insights ETF ACSG | 0.30% | 77.2K | 0.49% |
| 6 | Optimize Strategy Index ETF OPTZ | 0.20% | 467.8K | 0.25% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.16% | 119.2K | 0.35% |
| 8 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.16% | 1.78M | 0.35% |
| 9 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.16% | 745.1K | 0.40% |
| 10 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.16% | 120.3K | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.30
Bearish
Buys
4
Sells
8
Shares acquired
16.2K
Shares disposed
54.5K
Cash buys
—
Cash sales
4.00
Net activity
-38,306
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 416 | 15.44 | 6.4K | 70,208 | D | ↗ |
| 2026-04-15 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 6,348 | 27.66 | 175.6K | 69,792 | D | ↗ |
| 2026-04-13 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 3,542 | 10.20 | 36.1K | 120,417 | D | ↗ |
| 2026-04-13 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 15,730 | 26.83 | 422.0K | 689,321 | D | ↗ |
| 2026-04-09 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 2,170 | 27.38 | 59.4K | 76,140 | D | ↗ |
| 2026-03-31 | Karydas Daphne | Director | M-Exempt | D | Stock Option | 3,000 | 12.02 | 36.1K | 41,000 | D | ↗ |
| 2026-03-31 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 19,364 | 25.50 | 493.8K | 760,687 | D | ↗ |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 58,300 | 24.16 | 1.41M | 5,825,521 | I | ↗ |
| 2026-03-27 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 310,700 | 23.67 | 7.35M | 5,767,221 | I | ↗ |
| 2026-03-17 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 417 | 15.44 | 6.4K | 76,557 | D | ↗ |
| 2026-03-13 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 3,542 | 10.20 | 36.1K | 86,031 | D | ↗ |
| 2026-03-12 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 6,348 | 1.08 | 6.9K | 88,837 | D | ↗ |
| 2026-03-09 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 2,171 | 16.00 | 34.7K | 84,660 | D | ↗ |
| 2026-03-04 | Warren Eric | Officer | — | — | Stock Option | 357,000 | 13.24 | 4.73M | 0 | D | ↗ |
| 2026-02-19 | Slingsby Brian Taylor | Director / 10% Owner | J-Other | A | Stock Option | 8,300 | 28.06 | 232.9K | 8,300 | I | ↗ |
| 2026-02-19 | SBLENDORIO GLENN | Director | A-Award | A | Common Stock | 6,200 | 0.00 | — | 6,200 | D | ↗ |
| 2026-02-19 | Rodman David Malcom | Officer | A-Award | A | Stock Option | 51,300 | 28.06 | 1.44M | 51,300 | D | ↗ |
| 2026-02-19 | RA CAPITAL MANAGEMENT, L.P. | Director | A-Award | A | Common Stock | 6,200 | 0.00 | — | 6,200 | I | ↗ |
| 2026-02-19 | Levy Adam Scott | Officer | A-Award | A | Common Stock | 39,900 | 0.00 | — | 48,538 | D | ↗ |
| 2026-02-19 | Karydas Daphne | Director | A-Award | A | Stock Option | 8,300 | 28.06 | 232.9K | 8,300 | D | ↗ |
| 2026-02-19 | Gold Alexander M | Director | A-Award | A | Stock Option | 8,300 | 28.06 | 232.9K | 8,300 | D | ↗ |
| 2026-02-19 | DiRocco Derek | Director | A-Award | A | Common Stock | 6,200 | 0.00 | — | 6,200 | D | ↗ |
| 2026-02-19 | Congleton Jon | Director / Officer | A-Award | A | Stock Option | 187,900 | 28.06 | 5.27M | 187,900 | D | ↗ |
| 2026-02-19 | AKKARAJU SRINIVAS | Director / 10% Owner | A-Award | A | Common Stock | 6,200 | 0.00 | — | 6,200 | D | ↗ |
| 2026-02-17 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 417 | 15.44 | 6.4K | 44,506 | D | ↗ |
| 2026-02-13 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 4,166 | 14.25 | 59.4K | 54,603 | D | ↗ |
| 2026-02-12 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 6,349 | 1.08 | 6.9K | 56,786 | D | ↗ |
| 2026-02-09 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 2,171 | 16.00 | 34.7K | 52,608 | D | ↗ |
| 2026-01-20 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 416 | 15.44 | 6.4K | 50,853 | D | ↗ |
| 2026-01-14 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 11,367 | 32.61 | 370.6K | 50,437 | D | ↗ |
| 2026-01-13 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 4,167 | 14.25 | 59.4K | 69,513 | D | ↗ |
| 2026-01-12 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 6,348 | 1.08 | 6.9K | 68,152 | D | ↗ |
| 2026-01-12 | Levy Adam Scott | Officer | S-Sale | D | Common Stock | 10,758 | 32.14 | 345.7K | 8,638 | D | ↗ |
| 2026-01-12 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 9,119 | 32.21 | 293.7K | 646,268 | D | ↗ |
| 2026-01-09 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 2,170 | 16.00 | 34.7K | 28,218 | D | ↗ |
| 2026-01-05 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 26,069 | 10.20 | 265.9K | 134,584 | D | ↗ |
| 2026-01-02 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 70,037 | 35.87 | 2.51M | 69,188 | D | ↗ |
| 2025-11-21 | Congleton Jon | Director / Officer | M-Exempt | A | Common Stock | 24,082 | 0.54 | 13.0K | 655,387 | D | ↗ |
| 2025-11-20 | Slingsby Brian Taylor | Director / 10% Owner | S-Sale | D | Common Stock | 1,000,000 | 43.35 | 43.35M | 7,903,838 | I | ↗ |
| 2025-11-13 | Karydas Daphne | Director | S-Sale | D | Common Stock | 10,115 | 45.81 | 463.4K | 4,885 | D | ↗ |
| 2025-11-13 | Gold Alexander M | Director | M-Exempt | A | Common Stock | 2,742 | 10.20 | 28.0K | 2,742 | D | ↗ |
| 2025-11-12 | Gold Alexander M | Director | S-Sale | D | Common Stock | 5,000 | 46.50 | 232.5K | 1,933 | D | ↗ |
| 2025-11-11 | Levy Adam Scott | Officer | S-Sale | D | Common Stock | 8,485 | 42.34 | 359.3K | 103,612 | D | ↗ |
| 2025-11-11 | Gold Alexander M | Director | M-Exempt | D | Stock Option | 15,000 | 10.20 | 153.0K | 17,900 | D | ↗ |
| 2025-11-11 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 32,850 | 46.89 | 1.54M | 631,305 | D | ↗ |
| 2025-10-15 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 10,369 | 43.01 | 446.0K | 71,155 | D | ↗ |
| 2025-10-13 | Levy Adam Scott | Officer | S-Sale | D | Common Stock | 7,366 | 41.90 | 308.7K | 120,257 | D | ↗ |
| 2025-10-13 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 13,548 | 42.63 | 577.5K | 832,857 | D | ↗ |
| 2025-09-15 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 9,302 | 35.90 | 333.9K | 83,589 | D | ↗ |
| 2025-09-04 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 1,176,470 | 25.50 | 30.00M | 5,456,521 | I | ↗ |
| 2025-09-04 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 588,235 | 25.50 | 15.00M | 588,235 | I | ↗ |
| 2025-08-13 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 11,365 | 12.93 | 147.0K | 92,891 | D | ↗ |
| 2025-08-12 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 6,349 | 1.08 | 6.9K | 82,531 | D | ↗ |
| 2025-07-30 | Levy Adam Scott | Officer | S-Sale | D | Common Stock | 8,425 | 15.10 | 127.2K | 132,934 | D | ↗ |
| 2025-07-29 | Levy Adam Scott | Officer | S-Sale | D | Common Stock | 807 | 14.00 | 11.3K | 192,859 | D | ↗ |
| 2025-07-28 | Levy Adam Scott | Officer | S-Sale | D | Common Stock | 12,946 | 14.04 | 181.8K | 193,666 | D | ↗ |
| 2025-07-14 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 6,349 | 1.08 | 6.9K | 109,273 | D | ↗ |
| 2025-07-11 | Levy Adam Scott | Officer | S-Sale | D | Common Stock | 10,758 | 14.45 | 155.5K | 206,612 | D | ↗ |
| 2025-07-11 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 15,884 | 14.51 | 230.4K | 846,405 | D | ↗ |
| 2025-06-13 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 11,366 | 14.60 | 165.9K | 101,651 | D | ↗ |
| 2025-06-12 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 6,348 | 1.08 | 6.9K | 95,229 | D | ↗ |
| 2025-05-14 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 11,366 | 15.29 | 173.8K | 106,669 | D | ↗ |
| 2025-05-12 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 6,349 | 1.08 | 6.9K | 118,035 | D | ↗ |
| 2025-04-14 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 6,348 | 1.08 | 6.9K | 123,052 | D | ↗ |
| 2025-04-11 | Levy Adam Scott | Officer | S-Sale | D | Common Stock | 10,757 | 12.06 | 129.7K | 215,340 | D | ↗ |
| 2025-04-11 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 15,319 | 12.19 | 186.8K | 862,289 | D | ↗ |
| 2025-04-01 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 30,574 | 15.00 | 458.5K | 141,901 | D | ↗ |
| 2025-03-13 | Slingsby Brian Taylor | Director / 10% Owner | P-Purchase | A | Common Stock | 259,259 | 13.50 | 3.50M | 8,903,838 | I | ↗ |
| 2025-03-13 | Samsara BioCapital GP, LLC | 10% Owner | P-Purchase | A | Common Stock | 600,000 | 13.50 | 8.10M | 5,674,916 | I | ↗ |
| 2025-03-13 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 1,296,296 | 13.50 | 17.50M | 4,280,051 | I | ↗ |
| 2025-03-13 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 600,000 | 13.50 | 8.10M | 5,674,916 | I | ↗ |
| 2025-03-12 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 6,349 | 1.08 | 6.9K | 170,869 | D | ↗ |
| 2025-02-13 | Slingsby Brian Taylor | Director / 10% Owner | J-Other | D | Stock Option | 32,900 | 10.20 | 335.6K | 0 | D | ↗ |
| 2025-02-13 | SBLENDORIO GLENN | Director | A-Award | A | Stock Option | 32,900 | 10.20 | 335.6K | 32,900 | D | ↗ |
| 2025-02-13 | Rodman David Malcom | Officer | A-Award | A | Stock Option | 170,000 | 10.20 | 1.73M | 170,000 | D | ↗ |
| 2025-02-13 | RA CAPITAL MANAGEMENT, L.P. | Director | A-Award | A | Stock Option (Right to Buy) | 32,900 | 10.20 | 335.6K | 32,900 | I | ↗ |
| 2025-02-13 | Levy Adam Scott | Officer | A-Award | A | Stock Option | 170,000 | 10.20 | 1.73M | 170,000 | D | ↗ |
| 2025-02-13 | Karydas Daphne | Director | A-Award | A | Stock Option | 32,900 | 10.20 | 335.6K | 32,900 | D | ↗ |
| 2025-02-13 | Gold Alexander M | Director | A-Award | A | Stock Option | 32,900 | 10.20 | 335.6K | 32,900 | D | ↗ |
| 2025-02-13 | DiRocco Derek | Director | A-Award | A | Stock Option | 32,900 | 10.20 | 335.6K | 32,900 | D | ↗ |
| 2025-02-13 | Congleton Jon | Director / Officer | A-Award | A | Stock Option | 570,000 | 10.20 | 5.81M | 570,000 | D | ↗ |
| 2025-02-13 | AKKARAJU SRINIVAS | Director / 10% Owner | A-Award | A | Stock Option | 32,900 | 10.20 | 335.6K | 32,900 | D | ↗ |
| 2025-02-12 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 6,348 | 1.08 | 6.9K | 164,520 | D | ↗ |
| 2025-01-13 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 5,018 | 0.54 | 2.7K | 151,823 | D | ↗ |
| 2025-01-13 | Levy Adam Scott | Officer | S-Sale | D | Common Stock | 10,657 | 9.09 | 96.9K | 226,197 | D | ↗ |
| 2025-01-13 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 18,333 | 9.06 | 166.1K | 877,608 | D | ↗ |
| 2024-12-11 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 5,017 | 0.54 | 2.7K | 146,008 | D | ↗ |
| 2024-11-11 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 5,026 | 15.00 | 75.4K | 140,991 | D | ↗ |
| 2024-11-06 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 25,482 | 1.08 | 27.5K | 161,456 | D | ↗ |
| 2024-10-14 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 5,352 | 1.08 | 5.8K | 165,434 | D | ↗ |
| 2024-10-11 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 5,017 | 0.54 | 2.7K | 15,052 | D | ↗ |
| 2024-10-11 | Levy Adam Scott | Officer | S-Sale | D | Common Stock | 10,757 | 13.57 | 146.0K | 236,854 | D | ↗ |
| 2024-10-11 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 15,271 | 13.52 | 206.4K | 895,941 | D | ↗ |
| 2024-09-12 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 6,349 | 1.08 | 6.9K | 125,605 | — | ↗ |
| 2024-09-11 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 5,018 | 0.54 | 2.7K | 119,256 | — | ↗ |
| 2024-08-12 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 6,348 | 1.08 | 6.9K | 177,135 | — | ↗ |
| 2024-07-24 | Slingsby Brian Taylor | Director / 10% Owner | S-Sale | D | Common Stock | 550,000 | 13.05 | 7.18M | 8,644,579 | — | ↗ |
| 2024-07-16 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 525 | 1.08 | 567.00 | 103,398 | — | ↗ |
| 2024-07-12 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 6,349 | 1.08 | 6.9K | 184,008 | — | ↗ |
| 2024-07-11 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 5,017 | 0.54 | 2.7K | 30,104 | — | ↗ |
| 2024-07-11 | Levy Adam Scott | Officer | S-Sale | D | Common Stock | 10,757 | 13.14 | 141.4K | 247,611 | — | ↗ |
| 2024-07-11 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 15,746 | 13.34 | 210.1K | 911,212 | — | ↗ |
| 2024-06-20 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 14,940 | 11.73 | 175.2K | 926,958 | — | ↗ |
| 2024-06-18 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 16,607 | 11.99 | 199.1K | 941,898 | — | ↗ |
| 2024-06-17 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 17,766 | 12.25 | 217.7K | 958,505 | — | ↗ |
| 2024-06-14 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 16,229 | 12.52 | 203.2K | 976,271 | — | ↗ |
| 2024-06-13 | Gold Alexander M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-13 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 39,961 | 12.74 | 509.0K | 992,500 | — | ↗ |
| 2024-06-12 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 6,349 | 1.08 | 6.9K | 190,357 | — | ↗ |
| 2024-06-12 | Congleton Jon | Director / Officer | S-Sale | D | Common Stock | 16,607 | 12.77 | 212.0K | 1,032,461 | — | ↗ |
| 2024-06-11 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 5,017 | 0.54 | 2.7K | 83,380 | — | ↗ |
| 2024-06-11 | Levy Adam Scott | Officer | S-Sale | D | Common Stock | 96,815 | 12.94 | 1.25M | 255,462 | — | ↗ |
| 2024-05-22 | Slingsby Brian Taylor | Director / 10% Owner | A-Award | A | Stock Option | 22,000 | 12.52 | 275.4K | 22,000 | — | ↗ |
| 2024-05-22 | SBLENDORIO GLENN | Director | A-Award | A | Stock Option | 22,000 | 12.52 | 275.4K | 22,000 | — | ↗ |
| 2024-05-22 | RA CAPITAL MANAGEMENT, L.P. | Director | A-Award | A | Stock Option | 22,000 | 12.52 | 275.4K | 22,000 | — | ↗ |
| 2024-05-22 | Litzka Olivier | Director | A-Award | A | Stock Option | 22,000 | 12.52 | 275.4K | 22,000 | — | ↗ |
| 2024-05-22 | Karydas Daphne | Director | A-Award | A | Stock Option | 22,000 | 12.52 | 275.4K | 22,000 | — | ↗ |
| 2024-05-22 | DiRocco Derek | Director | A-Award | A | Stock Option | 22,000 | 12.52 | 275.4K | 22,000 | — | ↗ |
| 2024-05-22 | AKKARAJU SRINIVAS | Director / 10% Owner | A-Award | A | Stock Option | 22,000 | 12.52 | 275.4K | 22,000 | — | ↗ |
| 2024-05-13 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 6,348 | 1.08 | 6.9K | 196,706 | — | ↗ |
| 2024-05-09 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 100 | 15.00 | 1.5K | 66,997 | — | ↗ |
| 2024-04-12 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 6,349 | 1.08 | 6.9K | 203,154 | — | ↗ |
| 2024-04-11 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 5,017 | 0.54 | 2.7K | 60,648 | — | ↗ |
| 2024-03-12 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 6,348 | 1.08 | 6.9K | 209,503 | — | ↗ |
| 2024-03-11 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 5,017 | 0.54 | 2.7K | 50,173 | — | ↗ |
| 2024-02-13 | Rodman David Malcom | Officer | A-Award | A | Stock Option | 200,000 | 14.25 | 2.85M | 200,000 | — | ↗ |
| 2024-02-13 | Levy Adam Scott | Officer | A-Award | A | Stock Option | 200,000 | 14.25 | 2.85M | 200,000 | — | ↗ |
| 2024-02-13 | Congleton Jon | Director / Officer | A-Award | A | Stock Option | 425,000 | 14.25 | 6.06M | 425,000 | — | ↗ |
| 2024-02-12 | Samsara BioCapital GP, LLC | 10% Owner | P-Purchase | A | Common Stock | 555,555 | 13.50 | 7.50M | 5,074,916 | — | ↗ |
| 2024-02-12 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 5,017 | 0.54 | 2.7K | 37,917 | — | ↗ |
| 2024-02-12 | RA CAPITAL MANAGEMENT, L.P. | Director | A-Award | A | Common Stock | 1,672,508 | 13.50 | 22.58M | 2,983,755 | — | ↗ |
| 2024-02-12 | AKKARAJU SRINIVAS | Director / 10% Owner | A-Award | A | Common Stock | 555,555 | 13.50 | 7.50M | 5,074,916 | — | ↗ |
| 2024-01-12 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 6,348 | 1.08 | 6.9K | 32,900 | — | ↗ |
| 2024-01-11 | Rodman David Malcom | Officer | M-Exempt | A | Common Stock | 5,017 | 0.54 | 2.7K | 26,552 | — | ↗ |
| 2023-12-11 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 5,018 | 0.54 | 2.7K | 65,224 | — | ↗ |
| 2023-11-22 | Congleton Jon | Director / Officer | P-Purchase | A | Common Stock | 4,250 | 5.97 | 25.4K | 1,049,068 | — | ↗ |
| 2023-11-13 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 5,017 | 0.54 | 2.7K | 70,242 | — | ↗ |
| 2023-11-03 | Rodman David Malcom | Officer | M-Exempt | D | Stock Option | 10,034 | 0.54 | 5.4K | 75,259 | — | ↗ |
| 2023-09-13 | SBLENDORIO GLENN | Director | A-Award | A | Stock Option | 44,000 | 12.02 | 528.9K | 44,000 | — | ↗ |
| 2023-09-13 | Karydas Daphne | Director | A-Award | A | Stock Option | 44,000 | 12.02 | 528.9K | 44,000 | — | ↗ |
| 2023-09-06 | Congleton Jon | Director / Officer | P-Purchase | A | Common Stock | 2,250 | 12.08 | 27.2K | 1,044,818 | — | ↗ |
| 2023-08-17 | Congleton Jon | Director / Officer | P-Purchase | A | Common Stock | 2,250 | 12.10 | 27.2K | 1,042,568 | — | ↗ |
| 2023-08-11 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 76,182 | 12.81 | 975.9K | 0 | — | ↗ |
| 2023-08-11 | Congleton Jon | Director / Officer | P-Purchase | A | Common Stock | 2,000 | 12.89 | 25.8K | 1,040,318 | — | ↗ |
| 2023-08-10 | Rodman David Malcom | Officer | S-Sale | D | Common Stock | 74,625 | 13.16 | 982.1K | 0 | — | ↗ |
| 2023-07-12 | Takahashi Takeshi | Director | J-Other | D | Stock Option | 44,000 | 16.00 | 704.0K | 0 | — | ↗ |
| 2023-07-12 | Slingsby Brian Taylor | Director / 10% Owner | J-Other | A | Stock Option | 88,000 | 16.00 | 1.41M | 88,000 | — | ↗ |
| 2023-03-17 | Rodman David Malcom | Officer | A-Award | A | Stock Option | 20,000 | 15.44 | 308.8K | 20,000 | — | ↗ |
| 2023-02-14 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 131,600 | 16.00 | 2.11M | 1,867,229 | — | ↗ |
| 2023-02-14 | HBM Healthcare Investments (Cayman) Ltd. | 10% Owner | C-Conversion | D | Series A Preferred Stock | 20,962,895 | 0.00 | — | 0 | — | ↗ |
| 2023-02-09 | Rodman David Malcom | Officer | — | D | Stock Option | 240,827 | 0.53 | 127.6K | 0 | — | ↗ |
| 2023-02-09 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | — | I | Series B Preferred Stock | 192,847 | 0.00 | — | 0 | — | ↗ |
| 2023-02-09 | HBM Healthcare Investments (Cayman) Ltd. | 10% Owner | — | D | Series A Preferred Stock | 1,941,368 | 0.00 | — | 0 | — | ↗ |
| 2023-02-09 | DiRocco Derek | Director | A-Award | A | Common Stock | 44,000 | 16.00 | 704.0K | 44,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
66.30M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jon Congleton President and Chief Executive Officer | 636.5K | — | — | 4.44M | 472.6K | — | 5.54M | 80.00% | ↗ |
| 2 | 2025 | David Rodman, M.D. Chief Medical Officer | 533.0K | 25.0K | — | 1.32M | 323.8K | — | 2.20M | 60.00% | ↗ |
| 3 | 2025 | Adam Levy Chief Financial Officer and Secretary | 532.0K | 25.0K | — | 1.32M | 323.2K | — | 2.20M | 60.05% | ↗ |
| 4 | 2024 | Jon Congleton President and Chief Executive Officer | 580.0K | — | — | 4.54M | 303.1K | — | 5.42M | 83.71% | ↗ |
| 5 | 2024 | David Rodman, M.D. Chief Medical Officer | 520.0K | — | — | 2.14M | 222.3K | — | 2.88M | 74.21% | ↗ |
| 6 | 2024 | Adam Levy Chief Financial Officer and Secretary | 500.0K | — | — | 2.14M | 213.8K | — | 2.85M | 74.95% | ↗ |
| 7 | 2023 | Jon Congleton Chief Executive Officer | 517.0K | — | — | 4.58M | 245.6K | 13.2K | 5.36M | 85.51% | ↗ |
| 8 | 2023 | Jon Congleton President and Chief Executive Officer | 517.0K | — | — | 4.58M | 245.6K | — | 5.34M | 85.73% | ↗ |
| 9 | 2023 | David Rodman, M.D. Chief Medical Officer | 500.0K | — | — | 1.62M | 213.8K | — | 2.33M | 69.42% | ↗ |
| 10 | 2023 | Adam Levy Chief Financial Officer and Secretary | 450.0K | 21.4K | — | 1.53M | 171.0K | — | 2.18M | 70.48% | ↗ |
| 11 | 2022 | Jon Congleton Chief Executive Officer | 416.7K | 72.5K | 1.12M | — | 120.8K | 12.2K | 1.74M | 64.25% | ↗ |
| 12 | 2022 | David Rodman, M.D. Chief Medical Officer | 411.5K | 71.5K | — | 492.1K | 119.2K | 12.2K | 1.11M | 44.47% | ↗ |
| 13 | 2022 | Adam Levy Chief Financial Officer and Secretary | 334.9K | — | 483.5K | — | 190.9K | 7.3K | 1.02M | 47.56% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jon Congleton | President, Chief Executive Officer & Director | 1M | male |
| David Rodman | Chief Medical Officer | 881.8K | — |
| Adam Scott Levy | Chief Financial Officer & Secretary | 880.2K | male |
| Brian Taylor Slingsby | Founder & Executive Director | 78.0K | — |
| Jessica Ibbitson | Executive Vice President of Operations | — | female |
| Robert McKean | Senior Vice President of CMC | — | — |
| Sarah Foster | Senior Vice President of People | — | female |
| Tiffany Ellen Burt | Senior Vice President of Medical Affairs | — | female |
| Danielle Mahoney | Senior Vice President of Quality Assurance | — | female |
| Eric J. Warren | Chief Commercial Officer | — | male |
| Jeffrey A. Munsie | Chief Legal Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MLYS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
